Skip to main content
SpringerLink
Log in

Pharmacologic Treatment of Panic Disorder

  • Chapter
  • First Online:
Behavioral Neurobiology of Anxiety and Its Treatment

Part of the book series: Current Topics in Behavioral Neurosciences ((CTBN,volume 2))

Abstract

Comprehensive management of panic disorder involves a wide array treatments and interventions to reduce symptoms and increase functionality. This chapter provides an overview of the pharmacologic treatment of panic disorder including aspects of assessment, treatment selection and the biologic mechanisms of the illness.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Abelson JL, Curtis GC (1996) Hypothalamic-pituitary-adrenal axis activity in panic disorder: prediction of long-term outcome by pretreatment cortisol levels. Am J Psychiatry 153(1):69–73

    PubMed  CAS  Google Scholar 

  • American Psychiatric Association (2009) Practice guideline for the treatment of persons with disorder, 2nd edn. American Psychiatric Association, Washington, DC

    Google Scholar 

  • Asnis GM, Hameedi FA et al (2001) Fluvoxamine in the treatment of panic disorder: a multi-center, double-blind, placebo-controlled study in outpatients. Psychiatry Res 103(1):1–14

    Article  PubMed  CAS  Google Scholar 

  • Barlow DH, Gorman JM et al (2000) Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: a randomized controlled trial. JAMA 283(19):2529–2536

    Article  PubMed  CAS  Google Scholar 

  • Berigan TR, Casas A et al (1998) Nefazodone and the treatment of panic. J Clin Psychiatry 59(5):256–257

    Article  PubMed  CAS  Google Scholar 

  • Blier P (2001) Pharmacology of rapid-onset antidepressant treatment strategies. J Clin Psychiatry 62(Suppl 15):12–27

    PubMed  CAS  Google Scholar 

  • Blier P, Abbott FV (2001) Putatuve mechanisms of action of antidepressant drugs in affective and anxiety disorders and pain. J Psychiatry Neurosci 26:37–43

    PubMed  CAS  Google Scholar 

  • Boyer W (1995) Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: a meta-analysis. Int Clin Psychopharmacol 10(1):45–49

    Article  PubMed  CAS  Google Scholar 

  • Bystritsky A, Rosen R et al (1999) Pilot open-label study of nefazodone in panic disorder. Depress Anxiety 10(3):137–139

    Article  PubMed  CAS  Google Scholar 

  • Canadian Psychiatric Association (2006) Clinical practice guidelines: management of anxiety disorders. Can J Psychiatry 51:275–277

    Google Scholar 

  • Carpenter LL, Leon Z et al (1999) Clinical experience with mirtazapine in the treatment of panic disorder. Ann Clin Psychiatry 11(2):81–86

    PubMed  CAS  Google Scholar 

  • Cottraux J, Note ID et al (1995) A controlled study of congnitive behaviour therapy with buspirone or placebo in panic disorder with agoraphobia. Br J Psychiatry 167:635–641

    Article  PubMed  CAS  Google Scholar 

  • Coupland NJ, Bell CJ et al (1996) Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmacol 16(5):356–362

    Article  PubMed  CAS  Google Scholar 

  • Cross-National and S. Group (1992) Drug treatment of panic disorder. Comparative efficacy of alprazolam, imipramine, and placebo. Cross-National Collaborative Panic Study, Second Phase Investigators [published erratum appears in Br J Psychiatry 1992 Nov;161:724] [see comments]. Br J Psychiatry 160:191–202; discussion 202–205

    Google Scholar 

  • Curtis CG, Massana J et al (1993) Maintenance drug therapy of panic disorder. J Psychiatr Res 27(Suppl 1):127–142

    Article  PubMed  Google Scholar 

  • Dager SR, Roy-Byrne P et al (1992) Long-term outcome of panic states during double-blind treatment and after withdrawal of aprazolam and placebo. Ann Clin Psychiatry 4:251–258

    Article  Google Scholar 

  • Dannon PN, Iancu I et al (2002) The efficacy of reboxetine in the treatment-refractory patients with panic disorder: an open label study. Hum Psychopharmacol 17(7):329–333

    Article  PubMed  CAS  Google Scholar 

  • Fava M (2006) Prospective studies of adverse events related to antidepressant discontinuation. J Clin Psychiatry 67(Suppl 4):14–21

    PubMed  CAS  Google Scholar 

  • Fisher AA, Davis MW (2002) Serotonin syndrome caused by selective serotonin reuptake-inhibitors-metoclopramide interaction. Ann Pharmacother 36(1):67–71

    Article  PubMed  Google Scholar 

  • Goddard AW, Gorman JM et al (1998) Neurobiology of panic disorder. In: Rosenbaum J, Pollack M (eds) Panic disorder and its treatment. Marcel Dekker, Inc, New York, pp 57–92

    Google Scholar 

  • Goddard AW, Brouette T et al (2001) Early coadministration of clonazepam with sertraline for panic disorder. Arch Gen Psychiatry 58(7):681–686

    Article  PubMed  CAS  Google Scholar 

  • Gorman JM, Kent JM (1999) SSRIs and SNRIs: broad spectrum of efficacy beyond major depression. J Clin Psychiatry 60(Suppl 4):33–38, discussion 39

    PubMed  Google Scholar 

  • Haas CK, Shekhar A et al (2009) Anxiety Drug Therapy. Encyclopedia of Neuroscience 499–508

    Google Scholar 

  • Hirschmann D, Dannon PN et al (2000) Pindolol augmentation in patients with treatment-resistant panic disorder: a double-blind, placebo-controlled trial. J Clin Psychopharmacol 20:556–559

    Article  PubMed  CAS  Google Scholar 

  • Hollifield M, Thompson PM et al (2005) Potential effectiveness and safety of olanzapine in refractory panic disorder. Depress Anxiety 21:33–40

    Article  PubMed  CAS  Google Scholar 

  • Howland RH (1996) Induction of mania with serotonin reuptake inhibitors. J Clin Psychopharmacol 16(6):425–427

    Article  PubMed  CAS  Google Scholar 

  • Jefferson JW (1997) Antidepressants in panic disorder. J Clin Psychiatry 58(Suppl 2):20–24, discussion 24–25

    PubMed  CAS  Google Scholar 

  • Jefferson JW (2001) Benzodiazepines and anticonvulsants for social phobia (social anxiety disorder). J Clin Psychiatry 62(Suppl 1):50–53

    PubMed  CAS  Google Scholar 

  • Johnson PL, Truitt W et al (2009) A key role for orexin in panic anxiety. Nat Med 16:111–115

    Article  PubMed  Google Scholar 

  • Kessler RC, McGonagle KA et al (1994) Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 51:8–19

    Article  PubMed  CAS  Google Scholar 

  • Krystal JH, D'Souza DC et al (2001) Current perspectives on the pathophysiology of schizophrenia, depression, and anxiety disorders. Med Clin North Am 85(3):559–577

    Article  PubMed  CAS  Google Scholar 

  • Leinonen E, Lepola U et al (2000a) Citalopram controls phobic symptoms in patients with panic disorder: randomized controlled trial. J Psychiatry Neurosci 25(1):25–32

    Google Scholar 

  • Leinonen E, Lepola U et al (2000b) Citalopram controls phobic symptoms in patients with panic disorder: randomized controlled trial. J Psychiatry Neurosci 25:24–32

    PubMed  CAS  Google Scholar 

  • Liebowitz MR, Hollander E et al (1990) Reversible and irreversible monoamine oxidase inhibitors in other psychiatric disorders. Acta Psychiatr Scand Suppl 360:29–34

    Article  PubMed  CAS  Google Scholar 

  • Londborg PD, Wolkow R et al (1998) Sertraline in the treatment of panic disorder. A multi-site, double-blind, placebo-controlled, fixed-dose investigation. Br J Psychiatry 173:54–60

    Article  PubMed  CAS  Google Scholar 

  • Louie AK, Lewis TB et al (1993) Use of low-dose fluoxetine in major depression and panic disorder. J Clin Psychiatry 54:435–438

    PubMed  CAS  Google Scholar 

  • Mancama D, Kerwin RW (2003) Role of pharmacogenomics in individualizing treatment with SSRI’s. CNS Drugs 17(3):143–151

    Article  PubMed  CAS  Google Scholar 

  • Mavissakalian MR, Perel JM (1994) Dose-response characterization of the antipanic effects of imipramine. Psychopharmacol Bull 30(2):171–174

    PubMed  CAS  Google Scholar 

  • Mavissakalian MR, Perel JM (2001) 2nd year maintenance and discontinuation of imipramine in panic disorder with agoraphobia. Ann Clin Psychiatry 13(2):63–67

    PubMed  CAS  Google Scholar 

  • McHugh RK, Smits JAJ et al (2009) Empirically supported treatments for panic disorder. Psychiatr Clin North Am 32:593–610

    Article  PubMed  Google Scholar 

  • Michelson D, Allgulander C et al (2001) Efficacy of usual antidepressant dosing regimens of fluoxetine in panic disorder: randomised, placebo-controlled trial. Br J Psychiatry 179:514–518

    Article  PubMed  CAS  Google Scholar 

  • Misri S, Burgmann A et al (2000) Are SSRIs safe for pregnant and breastfeeding women? Can Fam Physician 46(626–628):631–633

    Google Scholar 

  • Moroz G, Rosenbaum JF (1999) Efficacy, safety, and gradual discontinuation of clonazepam in panic disorder: a placebo-controlled, multicenter study using optimized dosages. J Clin Psychiatry 60:604–612

    Article  PubMed  CAS  Google Scholar 

  • Munjack DJ, Crocker B et al (1989) Alprazolam, propranolol, and placebo in the treatment of panic disorder and agoraphobia with panic attacks. J Clin Psychopharmacol 9:22–27

    PubMed  CAS  Google Scholar 

  • Murphy TK, Bengtson MA et al (2000) Selective serotonin reuptake inhibitors in the treatment of paediatric anxiety disorders: a review. Int Clin Psychopharmacol 15(Suppl 2):S47–S63

    PubMed  Google Scholar 

  • Noyes R, Burrows GD et al (1996) Diazepam versus alprazolam for the treatment of panic disorder. J Clin Psychiatry 57:349–355

    PubMed  CAS  Google Scholar 

  • Otto MW, Tuby KS et al (2001) An effect-size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder. Am J Psychiatry 158(12):1989–1992

    Article  PubMed  CAS  Google Scholar 

  • Otto MW, Tolin DF et al (in press) Efficacy of d-cycloserine for enhancing response to cognitive behavioral therapy for panic disorder. Biol Psychiatry

    Google Scholar 

  • Pande AC, Pollack MH et al (2000) Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol 20:467–471

    Article  PubMed  CAS  Google Scholar 

  • Perna G, Bertani A et al (2001) A comparison of citalopram and paroxetine in the treatment of panic disorder: a randomized, single-blind study. Pharmacopsychiatry 34(3):85–90

    Article  PubMed  CAS  Google Scholar 

  • Pitman RK, Sanders KM et al (2002) Pilot study of secondary prevention of posttraumatic stress disorder with propranolol. Biol Psychiatry 51(2):189–192

    Article  PubMed  CAS  Google Scholar 

  • Plotsky P, Owens M et al (1995) Neuropeptide alterations in mood disorders. In: Bloom F, Kupfer D (eds) Psychopharmacology: the fourth generation of progress. Raven Press, New York, pp 971–982

    Google Scholar 

  • Pohl RB, Wolkow RM et al (1998) Sertraline in the treatment of panic disorder: a double-blind multicenter trial. Am J Psychiatry 155(9):1189–1195

    PubMed  CAS  Google Scholar 

  • Pollack MH, Worthington JJ et al (1997) Abecarnil for the treatment of generalized anxiety disorder: a placebo-controlled comparison of two dosage ranges of abecarnil and buspirone. J Clin Psychiatry 58(Suppl 11):19–23

    PubMed  CAS  Google Scholar 

  • Pollack MH, Otto MW et al (1998) Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial. Arch Gen Psychiatry 55(11):1010–1016

    Article  PubMed  CAS  Google Scholar 

  • Pollack MH, Simon NM et al (2003) Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorder. J Psychopharmacol 17:276–282

    Article  PubMed  CAS  Google Scholar 

  • Rapaport MH, Wolkow R et al (2001) Sertraline treatment of panic disorder: results of a long-term study. Acta Psychiatr Scand 104(4):289–298

    Article  PubMed  CAS  Google Scholar 

  • Ravaris CL, Friedman MJ et al (1991) A controlled study of alprazolam and propranolol in panic-disordered and agoraphobic outpatients. J Clin Psychopharmacol 11:344–350

    Article  PubMed  CAS  Google Scholar 

  • Reinscheid RK (2008) Neuropeptide S: anatomy, pharmacology, genetics and physiological functions. Results Probl Cell Differ 46:145–158

    Article  PubMed  CAS  Google Scholar 

  • Reul JM, Labeur MS et al (1994) Hypothalamic-pituitary-adrenocortical axis changes in the rat after long-term treatment with the reversible monoamine oxidase-A inhibitor moclobemide. Neuroendocrinology 60(5):509–519

    Article  PubMed  CAS  Google Scholar 

  • Robins LN, Helzer JE et al (1984) Lifetime prevalence of specific psychiatric disorders in three sites. Arch Gen Psychiatry 41:949–958

    Article  PubMed  CAS  Google Scholar 

  • Rosenbaum JF, Pollock RA et al (1996) The pharmacotherapy of panic disorder. Bull Menninger Clin 60(Suppl A):A54–A75

    PubMed  CAS  Google Scholar 

  • Rotondo A, Mazzanti C et al (2002) Catechol o-methyltransferase, serotonin transporter, and tryptophan hydroxylase gene polymorphisms in bipolar disorder patients with and without comorbid panic disorder. Am J Psychiatry 159(1):23–29

    Article  PubMed  Google Scholar 

  • Royal Australian and New Zealand College of Psychiatrists (2003) Australian and New Zealand clinical practice guidelines for the treatment of panic disorder and agoraphobia. Aust N Z J Psychiatry 37:641–656

    Article  Google Scholar 

  • Roy-Byrne PP, Clary CM et al (2001) The effect of selective serotonin reuptake inhibitor treatment of panic disorder on emergency room and laboratory resource utilization. J Clin Psychiatry 62(9):678–682

    Article  PubMed  CAS  Google Scholar 

  • Roy-Byrne PP, Craske MG, Stein MB (2006) Panic disorder. Lancet 368:1023–1032

    Article  PubMed  Google Scholar 

  • Rupprecht R, Rammes G et al (2009) Translocator protein (18 kD) as target for anxiolytics without benzodiazepine-like side effects. Science 325:490–493

    Article  PubMed  CAS  Google Scholar 

  • Savoldi F, Somenzini G et al (1990) Etizolam versus placebo in the treatment of panic disorder with agoraphobia: a double-blind study. Curr Med Res Opin 12:185–190

    Article  PubMed  CAS  Google Scholar 

  • Schmitt U, Hiemke C (1999) Effects of GABA-transporter (GAT) inhibitors on rat behaviour in open-field and elevated plus-maze. Behav Pharmacol 10(2):131–137

    Article  PubMed  CAS  Google Scholar 

  • Schweizer E, Clary C et al (1992) The use of low-dose intranasal midazolam to treat panic disorder: a pilot study. J Clin Psychiatry 53:19–22

    PubMed  CAS  Google Scholar 

  • Schweizer E, Rickels K et al (1993) Maintenance drug treatment of panic disorder: I. results of a prospective, placebo-controlled comparison of aprazolam and Imipramine. Arch Gen Psychiatry 50:51–60

    Article  PubMed  CAS  Google Scholar 

  • Selak I (2001) Pregabalin (Pfizer). Curr Opin Invest Drugs 2(6):828–834

    CAS  Google Scholar 

  • Sheehan DV, Raj AB et al (1993) The relative efficacy of high-dose buspirone and alprazolam in the treatment of panic disorder: a double-blind placebo-controlled study. Acta Psychiatr Scand 88:1–11

    Article  PubMed  CAS  Google Scholar 

  • Sheikh JI, Lonborg P et al (2000) The efficacy of sertraline in panic disorder: combined results from two fixed-dose studies. Int Clin Psychopharmacol 15:335–342

    Article  PubMed  CAS  Google Scholar 

  • Shekhar A, Keim SR (2000) LY354740, a potent group II metabotropic glutamate receptor agonist prevents lactate-induced panic-like response in panic-prone rats. Neuropharmacology 39(7):1139–1146

    Article  PubMed  CAS  Google Scholar 

  • Shelton RC (2006) The nature of discontinuation syndrome associated with antidepressant drugs. J Clin Psychiatry 67(Suppl 4):3–7

    PubMed  CAS  Google Scholar 

  • Simon NM, Hoge EA et al (2006) An open-label trial of risperidone augmentation for refractory anxiety disorders. J Clin Psychiatry 67:381–385

    Article  PubMed  CAS  Google Scholar 

  • Stein MB (2005) Anxiety disorders: somatic treatment. In: Kaplan HI, Sadock BJ (eds) Comprehensive textbook of psychiatry. Lippincott, Williams, & Wilkins, Philadelphia, PA

    Google Scholar 

  • Stein MB, Sareen J et al (2001) Pindolol potentiation of paroxetine for generalized social phobia: a double-blind, placebo-controlled, crossover study. Am J Psychiatry 158(10):1725–1727

    Article  PubMed  CAS  Google Scholar 

  • Stein MB, Kline NA et al (2002) Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study. Am J Psychiatry 159(10):1777–1779

    Article  PubMed  Google Scholar 

  • Szabo ST, Blier P (2001) Effects of chronic antidepressant drug administration and electroconvulsive shock on locus coeruleus electrophysiologic activity. Biol Psychiatry 50(8):644–646

    Article  PubMed  CAS  Google Scholar 

  • Szabo ST, de Montigny C et al (2000) Progressive attenuation of the firing activity of locus coeruleus noradrenergic neurons by sustained administration of selective serotonin reuptake inhibitors. Int J Neuropsychopharmacol 3(1):1–11

    Article  PubMed  CAS  Google Scholar 

  • Tesar GE, Rosenbaum JF et al (1991) Double-blind, placebo-controlled comparison of clonazepam and alprazolam for panic disorder. J Clin Psychiatry 52:69–76

    PubMed  CAS  Google Scholar 

  • Tiller JW, Bouwer C et al (1999) Moclobemide and fluoxetine for panic disorder. International Panic Disorder Study Group. Eur Arch Psychiatry Clin Neurosci 249(Suppl 1):S7–S10

    Article  PubMed  Google Scholar 

  • Tiwari AK, Souza RP et al (2009) Pharmacogenetics of anxiolytic drugs. J Neural Transm 116:667–677

    Article  PubMed  CAS  Google Scholar 

  • Tucker P, Adamson P et al (1997) Paroxetine increases heart rate variability in panic disorder. J Clin Psychopharmacol 17(5):370–376

    Article  PubMed  CAS  Google Scholar 

  • Valenca AM, Nardi AE et al (2003) Therapeutic response to benzodiazepine in panic disorder subtypes. Sao Paulo Med J 121:77–80

    Article  PubMed  Google Scholar 

  • van Vliet IM, Westenberg HG et al (1993) MAO inhibitors in panic disorder: clinical effects of treatment with brofaromine. A double blind placebo controlled study. Psychopharmacology (Berl) 112(4):483–489

    Article  Google Scholar 

  • Versiani M, Cassano G et al (2002) Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder. J Clin Psychiatry 63(1):31–37

    Article  PubMed  CAS  Google Scholar 

  • Walker DL, Ressler KJ et al (2002) Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of d-cycloserine as assessed with fear-potentiated startle in rats. J Neurosci 22(6):2343–2351

    PubMed  CAS  Google Scholar 

  • Weintrob N, Cohen D et al (2002) Decreased growth during therapy with selective serotonin reuptake inhibitors. Arch Pediatr Adolesc Med 156(7):696–701

    PubMed  Google Scholar 

  • Weissman MM, Markowitz JS et al (1990) Panic disorder and cardiovascular/cerebrovascular problems: results from a community survey [see comments]. Am J Psychiatry 147:1504–1508

    PubMed  CAS  Google Scholar 

  • Woodman CL, Noyes R Jr (1994) Panic disorder: treatment with valproate. J Clin Psychiatry 55:134–136

    PubMed  CAS  Google Scholar 

  • Zwanzger P, Eser D et al (2009) Changes in CCK-4 induced panic after treatment with the GABA-reuptake inhibitor tiagabine are associated with an increase in 3ά, 5ά-tetrahydrodeoxycorticosterone concentrations. Psychoneuroendocrinology 34:1586–1589

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Indiana University School of Medicine, Indianapolis, IN, 46202, USA

    Murray Stein, Thomas Steckler, Jeffrey D. Lightfoot, Elizabeth Hay & Andrew W. Goddard

Authors
  1. Murray Stein
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas Steckler
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jeffrey D. Lightfoot
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Elizabeth Hay
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Andrew W. Goddard
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Dept. Psychiatry, University of California, San Diego, Gilman Drive 9500, La Jolla, 92093-0985, USA

    Murray B. Stein

  2. Research & Development, CNS - Affective Spectrum, Johnson & Johnson Pharmaceutical, Turnhoutseweg 30, Beerse, 2340, Belgium

    Thomas Steckler

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Stein, M., Steckler, T., Lightfoot, J.D., Hay, E., Goddard, A.W. (2010). Pharmacologic Treatment of Panic Disorder. In: Stein, M., Steckler, T. (eds) Behavioral Neurobiology of Anxiety and Its Treatment. Current Topics in Behavioral Neurosciences, vol 2. Springer, Berlin, Heidelberg. https://doi.org/10.1007/7854_2009_35

Download citation

Publish with us

Policies and ethics

Search

Navigation